Video

Dr. Agarwal on Unmet Needs in mRCC

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses unmet needs in metastatic renal cell carcinoma (mRCC).

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses unmet needs in metastatic renal cell carcinoma (mRCC).

There is a great deal of unmet need in mRCC even though overall survival has gone from 1 year to approximately 3 to 4 years. More work needs to be done to develop novel agents and combinations, says Agarwal. Arguably even more importantly, biomarkers need to be identified in order to minimize cost and toxicity and improve patient selection, he adds.

In terms of available therapies, the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) has already been approved by the FDA for use in the first-line setting. The combinations of axitinib (Inlyta) and avelumab (Bavencio) as well as axitinib and pembrolizumab (Keytruda) are likely to receive regulatory approval in 2019, Agarwal predicts. Beyond first-line treatment, the most valuable agent is cabozantinib (Cabometyx), which has proven to be superior to conventional VEGF TKIs, such as sunitinib (Sutent) or, in the context of the METEOR trial, everolimus (Afinitor). Moreover, the agent appears to be more favorable than the combination of lenvatinib and everolimus, in terms of cost and toxicity, concludes Agarwal.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity